Monte Rosa Therapeutics Inc. reports fourth-quarter and full-year 2025 results Thursday, closing out a year marked by promising clinical data but facing investors’ questions about revenue ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

The S&P/ASX 200 closed 93.6 points higher, up 1.09%.

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from ...

Tommy DeCarlo, a singer who went from posting covers on MySpace to touring as Boston's lead vocalist for years, has died at ...

Monte Rosa Therapeutics recently reported updated Phase 1/2 data showing that its investigational GSPT1 degrader MRT-2359, in combination with enzalutamide, was well-tolerated and produced positive ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...